AMRI and Cystic Fibrosis Foundation Launch Major Research Collaboration
News Oct 05, 2007
AMRI and Cystic Fibrosis Foundation Therapeutics, Inc. announced a four-year research collaboration worth up to $23.7 million, aimed at identifying novel treatments that address the core defect in cystic fibrosis.
The agreement calls for AMRI to screen its natural-product based libraries to find compounds that improve the function of the defective protein in CF, known as the cystic fibrosis transmembrane conductance regulator (CFTR).
AMRI will also conduct an integrated drug discovery program-including chemistry and in vitro biology, on promising compounds that may emerge from the screening program. Should any compounds identified under the agreement progress into preclinical or clinical testing, AMRI has the option to provide chemical development and GMP manufacturing services to CFFT on those compounds.
The announcement is being made in conjunction with the 21st Annual North American Cystic Fibrosis Conference in Anaheim, Calif.
"With this collaboration, we are proving once again that we will explore every promising avenue to find new therapies for people with CF,” said Robert J. Beall, Ph.D., President and CEO of the Cystic Fibrosis Foundation. “We are excited about the potential of AMRI’s cutting-edge natural products capabilities to complement our existing small molecule drug discovery strategy.”
CFFT is exploring the promise of natural products in an effort to increase the number and diversity of chemicals available to improve the function of the defective CFTR protein.
The collaboration includes financial commitments from CFFT, which could be worth up to $23.7 million, if specific clinical development milestones are met.
The collaboration with CFFT marks AMRI’s fourth natural products-based research agreement in the last ten months, including two others that have previously been announced.
Old age is the greatest risk factor for many diseases, including Alzheimer's disease (AD) and cancer. Geroprotectors are a recently identified class of anti-aging compounds. New research has now identified a unique subclass of these compounds, dubbed geroneuroprotectors (GNPs), which are AD drug candidates and slow the aging process in mice.READ MORE